52North has announced a $6million funding round that marks the first instance of an investment being co-led by leading ...
Technology companies continue to hold most of the top spots in the annual Management Top 250 ranking of America’s best-run ...
The value of mergers and acquisitions involving UK companies, whether buying or selling, has increased by 57 per cent to ...
Ross McKenzie, who has held senior positions at big-name agencies, says Open Moove solves the deep-rooted inefficiencies in ...
Janssen-Cilag International NV, a Johnson & Johnson company, today announced new frontline data featuring TECVAYLI®▼ (teclistamab) from two investigational studies in patients with newly diagnosed ...
Use strategic price points for investments, aiming for a 15% discount from current prices. Click here to read more about the ...
AI and deep tech are permeating through Australia’s startup sector, while founders are getting older and increasingly eyeing ...
Teclistamab is an off-the-shelf (or ready to use) bispecific antibody. 6 Teclistamab, a subcutaneous injection, redirects T-cells through two cellular targets (BCMA and CD3) to activate the body's ...
Nijmegen, The Netherlands-based Alveron Pharma, a clinical-stage company, announced on Monday that it has secured €5M in a ...
Sutures by type are subdivided into absorbable sutures and nonabsorbable sutures. By material, the market is fragmented into monofilament and multifilament. By application, it is classified into ...
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated ...
Johnson & Johnson today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and ...